An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms

Boehringer Ingelheim

Status and phase: Completed; Phase 2

Conditions: Lower Urinary Tract Symptoms

Treatments: Drug: tamsulosin

Study type: Interventional

Funder types: Industry

Identifiers

NCT01726270

527.82

Details and patient eligibility

About

Multicenter trial conducted in Pharmacy retail centers

Enrollment: 689 patients

Sex: Male

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Men 18 years of age and older.
2. Able to speak, read and understand English.
3. Willing to participate in the study and voluntarily sign an informed consent document.

Exclusion criteria

1. Subject or anyone in their household is currently employed by a marketing or marketing research company, and advertising agency or public relations firm, a pharmacy or pharmaceutical company, a manufacturer of medicines, a managed care or health insurance company as a healthcare professional or healthcare practice.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

689 participants in 1 patient group

tamsulosin hydrochloride

Experimental group

Description:

patients will take drug for 8 weeks in this exploratory study

Treatment:

Drug: tamsulosin